Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

891 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of 18F-FDG PET for evaluating malignant pleural mesothelioma.
Nanni C, Castellucci P, Farsad M, Pinto C, Moretti A, Pettinato C, Marengo M, Boschi S, Franchi R, Martoni A, Monetti N, Fanti S. Nanni C, et al. Among authors: moretti a. Cancer Biother Radiopharm. 2004 Apr;19(2):149-54. doi: 10.1089/108497804323071913. Cancer Biother Radiopharm. 2004. PMID: 15186594 Clinical Trial.
18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin.
Ambrosini V, Nanni C, Rubello D, Moretti A, Battista G, Castellucci P, Farsad M, Rampin L, Fiorentini G, Franchi R, Canini R, Fanti S. Ambrosini V, et al. Among authors: moretti a. Radiol Med. 2006 Dec;111(8):1146-55. doi: 10.1007/s11547-006-0112-6. Epub 2006 Dec 20. Radiol Med. 2006. PMID: 17171520 English, Italian.
18F-FDG PET early after radiotherapy in lymphoma patients.
Castellucci P, Zinzani P, Nanni C, Farsad M, Moretti A, Alinari L, Battista G, Pettinato C, Marengo M, Boschi S, Canini R, Baccarani M, Monetti N, Fanti S. Castellucci P, et al. Among authors: moretti a. Cancer Biother Radiopharm. 2004 Oct;19(5):606-12. doi: 10.1089/cbr.2004.19.606. Cancer Biother Radiopharm. 2004. PMID: 15650453
Scintigraphic findings in necrotizing myopathy.
Nanni C, Fanti S, Pinto C, Farsad M, Moretti A, Franchi R, Martoni A, Monetti N. Nanni C, et al. Among authors: moretti a. Clin Nucl Med. 2003 Feb;28(2):118-20. doi: 10.1097/01.RLU.0000048484.23198.E8. Clin Nucl Med. 2003. PMID: 12544128
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, Lorenzi E, Perrino M, Giordano L, Farina G, Santoro A, Garassino M. Zucali PA, et al. Among authors: moretti a. Lung Cancer. 2012 Mar;75(3):360-7. doi: 10.1016/j.lungcan.2011.08.011. Epub 2011 Sep 19. Lung Cancer. 2012. PMID: 21937142
Limited Usefulness of 18F-FDG PET/CT in Predicting Tumor Regression After Preoperative Chemotherapy for Noncardia Gastric Cancer: The Italian Research Group for Gastric Cancer (GIRCG) Experience.
Morgagni P, Bencivenga M, Colciago E, Tringali D, Giacopuzzi S, Framarini M, Saragoni L, Mura G, Graziosi L, Marino E, Fumagalli Romario U, Baiocchi G, Moretti A, Rossi V, Verlato G. Morgagni P, et al. Among authors: moretti a. Clin Nucl Med. 2020 Mar;45(3):177-181. doi: 10.1097/RLU.0000000000002911. Clin Nucl Med. 2020. PMID: 31977470
891 results